NRX Income Quality vs Free Cash Flow Yield Analysis
NRXP Stock | USD 1.18 0.03 2.48% |
NRX Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating NRX Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NRX Pharmaceuticals is a good investment. Please check the relationship between NRX Pharmaceuticals Income Quality and its Free Cash Flow Yield accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NRX Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in NRX Stock, please use our How to Invest in NRX Pharmaceuticals guide.
Income Quality vs Free Cash Flow Yield
Income Quality vs Free Cash Flow Yield Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NRX Pharmaceuticals Income Quality account and Free Cash Flow Yield. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between NRX Pharmaceuticals' Income Quality and Free Cash Flow Yield is -0.1. Overlapping area represents the amount of variation of Income Quality that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of NRX Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of NRX Pharmaceuticals' Income Quality and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Quality of NRX Pharmaceuticals are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Income Quality i.e., NRX Pharmaceuticals' Income Quality and Free Cash Flow Yield go up and down completely randomly.
Correlation Coefficient | -0.1 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Most indicators from NRX Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NRX Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NRX Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in NRX Stock, please use our How to Invest in NRX Pharmaceuticals guide.As of 12/11/2024, Selling General Administrative is likely to grow to about 20.3 M, while Issuance Of Capital Stock is likely to drop slightly above 8.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 94.4M | 44.4M | 27.6M | 32.9M | Cost Of Revenue | 2K | 4K | 5K | 4.8K |
NRX Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
NRX Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NRX Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 32.1M | 2.9M | 32.7M | 25.8M | 7.3M | 6.9M | |
Other Current Liab | 7.6K | 42.7M | 7.7M | 5.8M | 5.3M | 9.7M | |
Total Current Liabilities | 622.4K | 46.2M | 11.9M | 16.6M | 19.0M | 14.9M | |
Total Stockholder Equity | 29.5M | (43.8M) | 20.8M | 7.4M | (11.7M) | (11.1M) | |
Net Debt | 2.0M | (1.1M) | (27.1M) | (9.5M) | 4.6M | 4.8M | |
Retained Earnings | 369.5K | (90.2M) | (183.2M) | (223.1M) | (253.1M) | (240.5M) | |
Accounts Payable | 622.4K | 3.2M | 3.7M | 2.1M | 4.6M | 2.3M | |
Cash | 6.0 | 1.9M | 27.6M | 20.1M | 4.6M | 8.6M | |
Non Current Assets Total | 32.0M | 11K | 15K | 21K | 431K | 409.5K | |
Non Currrent Assets Other | 1.0 | 11K | 15K | 21K | 431K | 452.6K | |
Cash And Short Term Investments | 6.0 | 1.9M | 27.6M | 20.1M | 4.6M | 8.6M | |
Common Stock Shares Outstanding | 508.8K | 34.3M | 46.9M | 65.8M | 7.6M | 7.2M | |
Liabilities And Stockholders Equity | 32.1M | 2.9M | 32.7M | 25.8M | 7.3M | 6.9M | |
Other Current Assets | 69.5K | 240K | 5.1M | 11.5M | 2.3M | 3.0M | |
Other Stockholder Equity | 29.1M | 46.4M | 204.0M | 230.3M | 241.3M | 253.4M | |
Total Liab | 2.6M | 46.7M | 11.9M | 18.4M | 19.0M | 15.7M | |
Total Current Assets | 69.5K | 2.9M | 32.7M | 25.8M | 6.9M | 10.8M | |
Common Stock | 24.5M | 43K | 59K | 67K | 84K | 79.8K | |
Short Long Term Debt Total | 2.0M | 797K | 518K | 10.5M | 9.2M | 9.6M |
Pair Trading with NRX Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NRX Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NRX Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with NRX Stock
Moving against NRX Stock
0.77 | BMY | Bristol Myers Squibb | PairCorr |
0.76 | GILD | Gilead Sciences | PairCorr |
0.64 | ESPR | Esperion Therapeutics | PairCorr |
0.45 | DNA | Ginkgo Bioworks Holdings | PairCorr |
0.44 | FLGC | Flora Growth Corp | PairCorr |
The ability to find closely correlated positions to NRX Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NRX Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NRX Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NRX Pharmaceuticals to buy it.
The correlation of NRX Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NRX Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NRX Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NRX Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.